Group 1 - The Hong Kong innovative drug sector experienced a decline, with the Hang Seng Innovative Drug Index dropping by 1.2% as of 14:45, while the Hang Seng Innovative Drug ETF (159316) saw a net subscription of 40 million units during the day [1] - Recent data from Wind indicates that the scale of the Hang Seng Innovative Drug ETF has increased by over 110% in the past month, reaching a historical high [1] - On August 6, Heng Rui Medicine announced that its product, injection of Rui Kang Qu Mo Zhuan Tan combined with A De Bei Li injection and chemotherapy for gastric cancer or gastroesophageal junction adenocarcinoma, received orphan drug designation from the FDA [1] Group 2 - On the same day, Di Zhe Medicine announced that its product DZD8586 received "Fast Track Designation" from the FDA [1] - According to a report from Industrial Securities, the innovative drug sector's prosperity is sustainable, with the trend of "innovation + internationalization" remaining a core direction for the pharmaceutical sector, supported by ongoing policies and expected global competitiveness [1] - The Hang Seng Innovative Drug Index recently announced a revision to its compilation scheme, explicitly excluding CXO companies and focusing on core innovative drug companies, with the new rules set to take effect on August 11 [1] Group 3 - The revised index will become one of the first "pure" innovative drug indices with 100% purity among the ETFs it tracks, providing investors with a convenient way to invest in leading innovative pharmaceutical companies [1]

Core Viewpoint - A new generation of fund managers is emerging in the public fund industry, demonstrating impressive performance by capitalizing on structural opportunities in the new consumption and innovative pharmaceutical sectors [1][2][4]. Group 1: Performance of Young Fund Managers - As of June 20, 2025, five out of the top ten actively managed equity funds have managers with less than three years of experience [2]. - Notable performances include Liang Furui's Changcheng Pharmaceutical Industry Selected Mixed Fund, which achieved a return of 71.21% this year, and was his first fund managed since its establishment in October 2023 [2]. - Another example is the Huazhong Pharmaceutical Biotechnology Stock Fund, managed by Sang Xiangyu, which has also exceeded a 60% return this year [2]. Group 2: Investment Focus and Background - Young fund managers have successfully identified opportunities in the innovative pharmaceutical sector, with many having strong professional backgrounds in relevant fields [4]. - Liang Furui has six years of experience in pharmaceutical research, while Sang Xiangyu has a dual background in bioengineering and economics, and Liu Haihao has been involved in consumer sector research for several years before becoming a fund manager [4]. Group 3: Market Conditions and Fund Establishment - The timing of fund establishment has been favorable, with several top-performing funds launched in late 2023, allowing managers to fully benefit from the rising innovative pharmaceutical market [5]. - The rapid establishment of these funds, often in a small scale, has enabled fund companies to effectively capitalize on market opportunities [5]. Group 4: Balancing Risk and Return - While young fund managers have shown strong performance, there is a need for them to learn how to manage drawdowns effectively, especially in a cyclical market [7]. - Funds with concentrated holdings, such as the Zhonghang Preferred Navigation Mixed Fund, have experienced significant volatility, highlighting the risks associated with aggressive investment strategies [7][8]. - Industry experts emphasize the importance of providing young managers with opportunities while also encouraging a shift towards long-term, value-oriented investment strategies as their fund sizes grow [8].

Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024 [1] - The average annual salary of CFOs in the chemical preparation sector of A-shares is 1.0448 million yuan [1] - The age distribution of CFOs shows that those aged 40-50 constitute 47% of the market, while those aged 60 and above account for only 4% [1] Group 2 - The top three highest-paid CFOs are Lü Hongbin from Dize Pharmaceutical with 4.2101 million yuan, Si Yanzha from Lizhu Group with 3.904 million yuan, and Lai Dequ from Kelun Pharmaceutical with 3 million yuan [2] - The largest salary decrease was observed for Xu Rongyi from Hainan Haiyao, with a year-on-year decline of 48.66% [2] - The highest salary increase was recorded for Wang Lin from Ailis, with a year-on-year increase of 104.6% [2]

Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024 [1] - The average annual salary of CFOs in the chemical preparation sector of A-share companies is 1.0448 million yuan [1] - The age distribution of CFOs shows that those aged 40-50 constitute 47% of the market, while those aged 60 and above account for only 4% [1] Group 2 - The top three highest-paid CFOs are Lü Hongbin from Dize Pharmaceutical with 4.2101 million yuan, Si Yanxia from Lizhu Group with 3.904 million yuan, and Lai Dequ from Kelun Pharmaceutical with 3 million yuan [2] - The largest salary decrease was observed for Xu Rongyi from Hainan Haiyao, with a year-on-year decline of 48.66% [2] - The highest salary increase was recorded for Wang Lin from Ailis, with a year-on-year increase of 104.6% [2]

责任编辑：公司观察 专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有87家上市化学制剂公司， 其聘任总体情况如下（部分统计口径剔除无效数据）。 从CFO的年龄分布来看，40岁-50岁CFO是市场的中坚力量，占比共计达到47%；60岁以上的CFO占比 为4%；50岁-60岁的CFO群体占比为39%；40岁及以下CFO群体占比为10%。其中，目前仍任职的最年 轻的上市公司CFO年龄33岁，为北陆药业的曾妮。 从CFO的学历分布看，拥有大专、本科、硕士、博士学历的CFO占比分别为9%、52%、38%、1%。其 中，获得博士学历的CFO仅一人，为恒瑞医药的刘健俊。 从薪酬分布看，A股化学制剂公司CFO年薪平均值为104.48万元。经统计，处于50万以下、50万-100 万、100万-20 ...

专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有87家上市化学制剂公司， 其聘任总体情况如下（部分统计口径剔除无效数据）。 从CFO的年龄分布来看，40岁-50岁CFO是市场的中坚力量，占比共计达到47%；60岁以上的CFO占比 为4%；50岁-60岁的CFO群体占比为39%；40岁及以下CFO群体占比为10%。其中，目前仍任职的最年 轻的上市公司CFO年龄33岁，为北陆药业的曾妮。 从CFO的学历分布看，拥有大专、本科、硕士、博士学历的CFO占比分别为9%、52%、38%、1%。其 中，获得博士学历的CFO仅一人，为恒瑞医药的刘健俊。 从薪酬分布看，A股化学制剂公司CFO年薪平均值为104.48万元。经统计，处于50万以下、50万-100 万、100万-200万、200万以上各 ...

从CFO的年龄分布来看，40岁-50岁CFO是市场的中坚力量，占比共计达到47%；60岁以上的CFO占比 为4%；50岁-60岁的CFO群体占比为39%；40岁及以下CFO群体占比为10%。其中，目前仍任职的最年 轻的上市公司CFO年龄33岁，为北陆药业的曾妮。 从CFO的学历分布看，拥有大专、本科、硕士、博士学历的CFO占比分别为9%、52%、38%、1%。其 中，获得博士学历的CFO仅一人，为恒瑞医药的刘健俊。 专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有87家上市化学制剂公司， 其聘任总体情况如下（部分统计口径剔除无效数据）。 其中，年薪排行前三的CFO分别为迪哲医药的吕洪斌、丽珠集团的司燕霞、科伦药业的赖德贵，三人年 薪分别为421.01万元、390.40万元、300 ...

分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有87家上市化学制剂公司， 其聘任总体情况如下（部分统计口径剔除无效数据）。 从CFO的年龄分布来看，40岁-50岁CFO是市场的中坚力量，占比共计达到47%；60岁以上的CFO占比 为4%；50岁-60岁的CFO群体占比为39%；40岁及以下CFO群体占比为10%。其中，目前仍任职的最年 轻的上市公司CFO年龄33岁，为北陆药业的曾妮。 从CFO的学历分布看，拥有大专、本科、硕士、博士学历的CFO占比分别为9%、52%、38%、1%。其 中，获得博士学历的CFO仅一人，为恒瑞医药的刘健俊。 专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 从薪酬变动幅度看（仅统计任职两年以上CFO薪资数据），海南海药（维权）的许荣义2024年薪酬降幅 最大，同比降幅达48.66%；艾力斯的王林薪酬 ...

分行业来看，统计数据显示，剔除未任职2024年全年董秘数据后，A股共有110家上市化学制剂公司， 其聘任总体情况如下（部分统计口径剔除无效数据）。 从董秘的年龄分布来看，40岁-50岁董秘是市场的中坚力量，占比共计达到46%；50岁以上的董秘占比 为21%；小于或等于40岁的董秘群体占比为33%。其中，目前仍任职的最年轻的男上市公司董秘年龄31 岁，为莎普爱思的黄明雄；最年轻的女董秘年龄为33岁，为百利天恒的陈英格。 专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 从董秘的学历分布看，拥有专科、本科、硕士、博士学历的董秘占比分别为7%、37%、50%、6%。其 中，获得博士学历的董秘共6人，分别为舒泰神的于茂荣、人福医药的李前伦、灵康药业的隋国平、海 正药业的沈锡飞、益方生物-U的江岳恒、健友股份的黄锡伟。其中，海正药业的沈锡飞为行业唯一一 个拥有博士学历的专职董秘。 从薪酬分 ...

Core Insights - The report highlights that in 2024, the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Over 21% of the secretaries earn more than 1 million yuan annually, indicating a significant portion of high-earning professionals in this role [1] Salary Distribution - The average annual salary for secretaries in the chemical preparation sector of A-share listed companies is 914,800 yuan [2] - Salary distribution shows that 33% earn below 500,000 yuan, 37% earn between 500,000 and 1 million yuan, 27% earn between 1 million and 2 million yuan, and 3% earn above 2 million yuan [2] - Four secretaries earn over 3 million yuan, with the highest being 5.2065 million yuan [2] Age Distribution - Secretaries aged between 40 and 50 years constitute 46% of the market, while those over 50 years account for 21%, and those aged 40 or below make up 33% [1] - The youngest male and female secretaries are 31 and 33 years old, respectively [1] Educational Background - The educational qualifications of secretaries show that 7% have an associate degree, 37% hold a bachelor's degree, 50% possess a master's degree, and 6% have a doctoral degree [2] - Only six secretaries hold a doctoral degree, with one being the only full-time secretary in the industry [2] Salary Changes - The largest salary decrease was observed for Wang Qin from ST Tian Sheng, with a year-on-year decline of 81.28% [2] - The highest salary increase was for Chen Bo from Huadong Medicine, with a year-on-year increase of 308.81% [2]